key: cord-1014227-jbslcj2n
authors: Yang, Siyuan; Hua, Mingxi; Liu, Xinzhe; Du, Chunjing; Pu, Lin; Xiang, Pan; Wang, Linghang; Liu, Jingyuan
title: Bacterial and fungal co-infections among COVID-19 patients in intensive care unit
date: 2021-03-05
journal: Microbes Infect
DOI: 10.1016/j.micinf.2021.104806
sha: fd3c6e8a1fb34768d6730c6215faecc014827e32
doc_id: 1014227
cord_uid: jbslcj2n

This study aimed to investigate the frequency and characteristics of respiratory co-infections in COVID-19 patients in the intensive care unit (ICU). In this retrospective observational study, pathogens responsible for potential co-infections were detected by the bacterial culture, real-time polymerase chain reaction (RT-PCR), or serological fungal antigen tests. Demographic and clinical characteristics, as well as microbial results, were analyzed. Bacterial culture identified 56 (58.3%) positive samples for respiratory pathogens, with the most common bacteria being Burkholderia cepacia (18, 18.8%). RT-PCR detected 38 (76.0%) and 58 (87.9%) positive results in the severe and critical groups, respectively. Most common pathogens detected were Stenotrophomonas maltophilia (28.0%) and Pseudomonas aeruginosa (28.0%) in the severe group and S. maltophilia (45.5%) in the critical group. P. aeruginosa was detected more during the early stage after ICU admission. Acinetobacter baumannii and S. aureus were more frequently identified during late ICU admission. Fungal serum antigens were more frequently positive in the critical group than in the severe group, and the positive rate of fungal serum antigens frequency increased with prolonged ICU stay. A high frequency of respiratory co-infections presented in ICU COVID-19 patients. Careful examinations and necessary tests should be performed to exclude these co-infections.

severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition to SARS-CoV-2, bacteria and fungi are reported to cause co-infections in critically ill patients with COVID-19, which increases its morbidity and mortality [1, 2] . Within the first few days after SARS-CoV-2 infection, critically ill patients with COVID-19 often develop respiratory tract distortion or pulmonary dysbiosis, which can further progress into a secondary bacterial or fungal infection few weeks later [3] [4] [5] . A study from Cambridge, UK, reported that a high percentage (9/14) of patients with COVID-19 in the intensive care unit (ICU) had confirmed secondary ventilator-associated pneumonia (VAP) [6] . The rapid and accurate identification of bacteria or fungi that present as pathogenic or resident microorganisms during the course of COVID-19 should be an important step during the management of COVID-19 patients [7] [8] [9] . However, the exact frequency of co-infections, the pathogens responsible for the co-infections, and the progress of the co-infections in critically ill patients with COVID-19 remain largely unknown.

In the present study, we analyzed the frequency and characteristics of respiratory co-infections among critically ill COVID-19 patients in the ICU.

This retrospective observational study included patients with confirmed COVID-19 who were admitted to the ICU at the Beijing Ditan Hospital, Capital J o u r n a l P r e -p r o o f Medical University, Beijing, China, from January 30, 2020 to April 13, 2020. The study was approved by the Ethics Committee of Beijing Ditan Hospital (KT2020-036-02).

The diagnosis of COVID-19 and the severity assessment were defined in accordance with the National Clinical Guidance for COVID-19 Diagnosis and Treatment of China (seventh edition) by the National Health Commission [10] . Severe patients were those patients with one of the following criteria: 1) no requirement for supplemental oxygen, 2) oxygen saturation at rest ≤ 93%, 3) respiratory rate more than 30 breaths/min, 4) respiratory distress. Critical patients were those with acute respiratory failure (PaO 2 /FiO 2 < 300, 30 > breaths/min), shock, organ failure required mechanical ventilation or intensive care management considered as critical. The demographics, gender, age, clinical data, and microbiology results were obtained from the electronic medical records.

Sputum and bronchoalveolar lavage (BAL) samples were collected for quantitative bacterial culture. Specimens were streaked on agar plates, including blood agar, MacConkey's, and chocolate agar, and then were incubated at 37°C (chocolate agar with 5% CO 2 ). After incubation for 24 and 48 hours, the bacteria were identified by a Phoneix-100 Automatic Microbiology System (BD, Maryland, USA).

The results were reported according to the standard of the National Guide to Clinical Laboratory Procedures of China (third edition) [11] . 

A total of 20 COVID-19 patients admitted to the ICU from January 30, 2020 to April 13, 2020 were included in this study. There were 7 patients (35.0%) in the severe group with the median age of 39 years (interquartile range, IQR, 36-67 years).

Thirteen patients (65.0%) were in the critical group with a median age of 69 years (IQR, 64-80 years). Compared to patients in the severe group, patients in the critical group was significantly older than in severe group (P < 0.01), and the length of stay in ICU of critical group was significantly (P < 0.01) longer than that of severe group.

The critical group including 4 cases (30.8%) had significantly (P = 0.005) higher rate of patients supported by extracorporeal membrane oxygenation (ECMO).

In these 13 critical patients, 23 BAL samples and 73 sputum samples were obtained for bacterial cultures. A total of 56 respiratory samples (58.3%) were identified to have respiratory bacterial pathogens ( Table 2 ). The two most common pathogens in the critical group were B. cepacia (18/ RT-PCR assay detected at least one bacterial pathogen in 38 of the 50 samples collected from the severe group, which yielded a positivity rate of 76.0% ( Table 2 ).

The most abundant pathogens were S. maltophilia (14, 28 .0%), P. aeruginosa (14, 28.0%), and A. baumannii (10, 20.0%). Multiple RT-PCR assay detected significantly more pathogens in 58 of 66 specimens from the critical group, yielding a higher positivity rate of 87.9%. The most prevalent bacteria were S. maltophilia (30, 45.5%).

The RT-PCR assay detected 31 more respiratory pathogens, including P. aeruginosa, E. coli, M. catarrhalis, H. influenzae, S. pneumoniae, and S. pyogenes, than the culture method. We note, however, that our RT-PCR assay was not designed to detect B. cepacia, M. morganii, and E. cloacae. L. pneumophila, M. tuberculosis, CP, MP, and PC were not detected in either the severe group or the critical group. Table 3 , in the 96 specimens with a positive result from the multiple RT-PCR assay, more than half (50, 52.1%) of the specimens had only one bacterium detected. Twenty-seven (28.1%), 12 (12.5%), and 7 (7.3) specimens had two, three, and four types of bacteria detected, respectively. There were no statistically significant differences in the frequency of different bacteria detected between the severe and critical groups (Table 3) .

In the severe group, at least one respiratory bacterial pathogen was detected in all 7 patients via multiple RT-PCR assay during the first five days after ICU admission, J o u r n a l P r e -p r o o f with the most common bacterium being P. aeruginosa (5/7, 71.4%) ( Figure 1A) .

Pathogens from the first specimens of 5 patients, including patients S2, S4, S5, S6, and S7, were still detected positive during the subsequent tested specimens. However, patients S1 and S3 had different pathogens detected in each subsequent tested specimen. Except patient S1, all other 6 patients had pathogens identified in the respiratory specimens after they were transferred to the general ward. In the severe group, the longest length of time for a positive respiratory bacterium, including K. pneumoniae, S. aureus and P. aeruginosa, was 22 days from patient S6. Bactria were still able to be identified from specimens from the 7 patients after their SARS-CoV-2 RT-PCR tests were negative.

In the critical group, bacteria were cultured from the respiratory samples from 9 out of 12 patients (except patients C2, C4 and C6). As shown in Figure 1B 

There was no significant difference in the positivity rates of the G test and GM test from specimens collected from patients in the severe group during the early, middle, and late stages of ICU admission (P > 0.05) ( Table 4 ). In the severe group, the positive rate of G tests increased to 57.1% during the middle stage and dropped to 50.0% in the late stage since only 4 patients stayed more than 12 days in the ICU. In the critical group, the rates of positive G tests and GM tests from the early and late stages were higher than those of the severe group. The positive G-test and GM-test rates tended to increase with the length of ICU stay, since the positive G-test rates from the late stage (84.6%) were much higher than that of the samples from the middle stage (69.2%) and early stage (46.2%).

In this study, we described the characteristics of co-infections in critically ill ICU patients with COVID-19. Culture results from sputum specimens or BAL specimens were available for 2 severe patients and 9 critical patients; however, there were no pathogens isolated in the early-stage specimens from the severe group, which might be due to the limited volume of the collected samples. In the critical group, B. cepacia and S. maltophilia were the two most common bacteria that were cultured. The majority of specimens that yielded a cultured organism were collected until 6 days after ICU admission. Most of the specimens collected during the late stage of ICU admission had a positive result from the bacterial culture. Thus far, previous studies have reported that the positive culture rates of respiratory bacterial pathogens from hospitalized patients with COVID-19 ranged from 2.0% to 17.2% [6, 8, 9] . The rate of bacterial co-infection in our study was higher than previous studies. This difference might be explained by the critical category, as well as the multiple times that the specimens were collected in our study [12] [13] [14] . This suggests that multiple attempts should be made to collect specimens from critically ill COVID-19 patients at different time points in order to identify pathogenic opportunistic bacteria. Additionally, a review, which included 806 COVID-19 cases, reported that a large percentage of COVID-19 patients (72%) received the broad-spectrum antimicrobial therapy. Our results showed that most of the cultured bacteria were detected during the middle and late stages of ICU admission. Thus, the selections and recommendations of empiric antimicrobial therapy for respiratory bacterial co-infection should not be only based on the results from early cultured specimens in critically ill patients with J o u r n a l P r e -p r o o f COVID-19 [15] .

We used a commercially available kit for the multiple respiratory pathogens RT-PCR assay, which is able to detect 15 respiratory pathogens. Compared with the microbial culture test, the multiple RT-PCR assay identified more bacteria in specimens from patients both in the severe group and critical group. The distribution of positive results from the multiple RT-PCR assay tended to appear during the early-stage and middle-stage of ICU admittance. S. maltophilia, S. aureus, P. aeruginosa, and A. baumannii were the most common bacteria detected in this study.

As these are frequently identified pathogens attributed to hospital-acquired pneumonia (HAP) in the ICU, it was difficult to distinguish colonization from infection due to the high sensitivity of the multiple RT-PCR assay [16] [17] [18] [19] . We also analyzed the distribution of pathogens identified using multiple RT-PCR assay throughout the ICU course. Our results showed that the multiple tests performed at different time points could improve the positive rates. A previous study showed that COVID-19 patients were more susceptible to developing VAP due to the increased duration of ventilation [20] . In our study, the majority of identified bacteria, either by culturing or multiple RT-PCR assay, were identified during the treatments without mechanical ventilation. Therefore, multiple RT-PCR assay in combination with a sensitive and rapid diagnostic test might shorten the time to pathogen identification and thereby decrease the risk of false-negative cultures, thus optimizing antimicrobial therapy in critically ill patients with COVID-19.

Respiratory viral infections, such as influenza, are recognized as an independent J o u r n a l P r e -p r o o f risk factor for co-infection with Aspergillus, which wis associated with a high mortality rate in critically ill patients admitted to the ICU. Positive (1,3)-β-D-glucan and galactomannan serum antigens in the critical group were more common than those in the severe group. However, Aspergillus was not identified in any specimens by culturing, which might be due to the frequent use of antifungal prophylaxis in these patients. However, the positive rate of fungal antigenemia was high, indicating that fungal co-infection among critically ill patients with COVID-19 should not be ignored [21] . Further studies on fungal co-infection need to address a more rapid serological assay or antifungal prophylaxis among critically ill patients with COVID-19.

Limitations of our study include a small sample size in a single study center. Our retrospective design also brought biases into the sample collection and comparisons. 

All authors declare that they have no conflicts of interest. and 1B, respectively. The results from specimens were classified as the date of patients admitted to the ICU. Patients S1 -7 had severe illness and patients C1 -13 had critical illness.

Note. a, the date of receiving mechanical ventilation; b, the date of supporting ECMO; ↑, the date of being transferred to the general ward.

J o u r n a l P r e -p r o o f 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Coronavirus Disease 2019 in China

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents

Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

The People's Republic of China. National Clinical Guidance for COVID-19

National guide to clinical laboratory procedures

Clinical Features of 69 Cases With Coronavirus Disease

Clinical Characteristics of Covid-19 in New York City

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study

Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients

An intervention to control an ICU outbreak of carbapenem-resistant Acinetobacter baumannii: long-term impact for the ICU and hospital

Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia

Risks and features of secondary infections in severe and critical ill COVID-19 patients

Fungal antigenemia in patients with severe Coronavirus disease 2019 (COVID-19): The facts and challenges

We would like to thank the frontline medical providers at Beijing Ditan Hospital for their bravery and efforts in the prevention and control of SARS-CoV-2.